

Batson, A. (2016), Global vaccine market. Global Vaccine and Immunization Research Forum. March 2016, available at: https://www.who.int/immunization/research/forums_and_initiatives/1_ABatson_Global_Vaccine_Market_gvirf16.pdf.

Beall, R. F. and Attaran, A. (2016), Global Challenges Report: Patent-based Analysis of the World Health Organization's 2013 Model List of Essential Medicines, Geneva: WIPO.

Beall, R. F. and Kesselheim, A. S. (2018), "Tertiary patenting on drug-device combination products in the United States", *Nature Biotechnology* 36: 142–145.

Beall, R. F., Darrow, J. J. and Kesselheim, A. S. (2019), "Patent term restoration for top-selling drugs in the United States", *Drug Discovery Today* 24(1): 20–25.

Beall, R. F., Nickerson, J. W., Kaplan, W. A. and Attaran, A. (2016),

- Cassini et al., 2019. "Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis", *The Lancet Infectious Diseases* 19(1): 56–66, available at: [http://dx.doi.org/10.1016/S1473-3099\(18\)30605-4](http://dx.doi.org/10.1016/S1473-3099(18)30605-4).
- de Chadarevian, S. (2011), "The Making of an Entrepreneurial Science: Biotechnology in Britain, 1975-1995", *Isis* 102(4): 601–633.
- Chakradhar, S. and Khamsi, R. (2017), "Angst about exclusivity: The potential cost of incentivizing makers of generic drugs", *Nature Medicine* 23(10): 1114–1116.
- Chandrasekharan S., Amin, T., Kim, J., Furrer, E., et al. "Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing-country vaccine manufacturers", *Vaccine* 33(46): 6366–6370.
- Chapman, N., Doubell, A., Oversteegen, L., Chowdhary, V., Rugarabamu, G., Zanetti, R. et al. (2017), *G-FINDER 2017: Neglected Disease Research and Development: Reflecting on a Decade of Global Investment*, Sydney: Policy Cures Research.
- Chaudhuri, S., Goldberg, P. K. and Jia, P. (2006), "Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India", *American Economic Review* 96(5): 1477–1514.
- Cheever, M. A. and Higano, C. S. (2011), "PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine", *Clinical Cancer Research* 17: 3520–3526.
- Cherny, N., Sullivan, R., Torode, J., Saar, M. and Eniu, A. (2016), "ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe", *Annals of Oncology* 27(8): 1423–1443.
- Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y. et al. (2017), "ESMO-Magnitude of Clinical Benefit Scale version 1.1", *Annals of Oncology* 28: 2340–2366.
- Cherny, N. I., Sullivan, R., Torode, J., Saar, M. and Eniu, A. (2017), "ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe", *Annals of Oncology* 28(11): 2633–2647.
- Chien, C. (2003), "Cheap Drugs at What Price to Innovation: Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation?", *Berkeley Technology Law Journal* 18(3): 853–907.
- Chopra, R. and Lopes, G. (2017), "Improving access to cancer treatments: The role of biosimilars", *Journal of Global Oncology* 3(5): 596–610.
- Christie, A.F., Dent, C., McIntyre, P., Wilson, L., et al. (2013), "Patents Associated with High-Cost Drugs in Australia", *PLoS ONE* 8(4): e60812, available at: <https://doi.org/10.1371/journal.pone.0060812>.
- Cleary, E. G., Beierlein, J. M., Khanuja, N. S., McNamee, L. M. and Ledley, F. D. (2018) Contribution of NIH funding to new drug approvals 2010–2016. *Proceedings of the National Academy of Sciences of the United States of America* 115(10): 2329–2334.
- Clendinen, C., Zhang, Y., Warburton, R. N., and Light, D. W. (2016), "Manufacturing costs of HPV vaccines for developing countries", *Vaccine* 34(48): 5984–5989.
- Cockburn, I. M. (2006), "Is the Pharmaceutical Industry in a Productivity Crisis?", in Jaffe, A. B., Lerner, J. and Stern, S. (eds.), *Innovation Policy and the Economy*, Volume 7, Cambridge (MA): National Bureau of Economic Research (NBER).
- Cockburn, I. M., Lanjouw, J. O. and Schankerman, M. (2016), "Patents and the global diffusion of new drugs", *American Economic Review* 106(1): 136–164.
- Cohen, J. (2017), "New CRISPR tool can detect tiny amounts of viruses", *Science*, online version, 13 April 2017.
- Cohen, W. M., Nelson, R. R. and Walsh, J. P. (2000), "Protecting Their Intellectual Assets: Appropriability Conditions and Why US Manufacturing Firms Patent (or Not)", Working Paper No. 7552, Cambridge (MA): National Bureau of Economic Research (NBER).
- Coller, B.G., Blue, J., Das, R., et al. (2017), "Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic", *Vaccine*

Correa, C. M. (2004), "Implementation of the WTO General Council Decision on Paragraph 6 of the DOHA Declaration on the TRIPS Agreement and Public Health", Health Economics and Drugs Series No. 016, Geneva: WHO.

Correa, C. M. (2016), Guidelines for Pharmaceutical Patent Examination: Examining Pharmaceutical Patents from a Public Health Perspective, New York: United Nations Development Programme (UNDP).

Costa Chaves, B., Gaspar Britto, W. and Fogaça Vieira, M. (2017), MERCOSUR-EU Free Trade Agreement: Impact Analysis of TRIPS-Plus Measures Proposed by the EU on Public Purchases and Domestic Production of HIV and Hepatitis C Medicines in Brazil, available at: <https://www.accessibsa.org/media/2018/01/Mercosur-EU-Free-Trade-Agreement-HIV-Hepatitis-C.pdf>.

Cotropia, C. A. (2008), "Compulsory Licensing Under TRIPS and the Supreme Court of the United States' Decision in eBay v. MercExchange", in Takenaka, T. and Moufang, R. (eds.), Patent Law: A Handbook of Contemporary Research, Edward Elgar Publishing Co, available at: <https://ssrn.com/abstract=1086142>.

Council for International Organizations of Medical Sciences (CIOMS) (2016), International Ethical Guidelines for Health-related Research Involving Humans, Geneva: CIOMS.

Creese, A. (2011), "Sales Taxes on Medicines", WHO/HAI Project on Medicine Prices and Availability, Review Series on Pharmaceutical Pricing Policies and Interventions, Working Paper 5, Geneva: WHO and HAI.

Ederigton, J. and Rutta, M. (2016), "Non-Tariff Measures and the World Trading System," World Bank Policy Research Paper, available at: <http://documents.worldbank.org/curated/en/882991467989523068/pdf/WPS7661.pdf>.

Elks, S. (2018), "Drug buyers' clubs aim to tackle HIV prevention 'crisis'", Thomson Reuters Foundation News, 3 December 2018, available at: <http://news.trust.org/item/20181130235707-qho8y/>.

Espin, J., Rovira, J. and Oly de Labry, A. (2011), "External Reference Pricing", WHO/HAI Project on Medicine Prices and Availability, Review Series on Pharmaceutical Pricing Policies and Interventions, Working Paper 1, Geneva: WHO

European Commission (2009a), Communication from the Commission: Executive Summary of the Pharmaceutical Sector Inquiry Report, available at: https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication_en.pdf.

European Commission (2009b), Pharmaceutical Sector Inquiry: Final Report: Adoption date: 8 July 2009, available in two parts at <https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/>.

European Commission (2014a), "German company wins EU's €2 million inducement prize for innovative vaccine technology", press release, 10 March 2014, available at: https://europa.eu/rapid/press-release_IP-14-229_en.htm?locale=EN.

European Commission (2014b), Medical Countermeasures That Could Be Procured in Common Under the Joint Procurement Agreement, available at: https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/jpa_note_scope_en.pdf.

European Commission (2017), "Antitrust: Commission opens formal investigation into Aspen Pharma's pricing practices for cancer medicines", press release, 15 May 2017, available at: http://europa.eu/rapid/press-release_IP-17-1323_en.htm.

European Commission (2018a), Innovative Payment Models for High-cost Innovative Medicines: Report of the Expert Panel on Effective Ways of Investing in Health (EXPH), Luxembourg: Publications Office of the European Union.

European Commission (2018b), EU R&D Scoreboard: The 2018 EU Industrial R&D Investment Scoreboard, Luxembourg: Publications Office of the European Commission.

European Commission (2019a), Competition Enforcement in the Pharmaceutical Sector (2009-2017): European Competition Authorities Working Together for Affordable and Innovative Medicines, Luxembourg: Publications Office of the European Union.

European Commission (2019b), Report on the EU Customs Enforcement of Intellectual Property Rights: Results at the EU Border 2018, Luxembourg: Publications Office of the European Commission.

European Commission, Pan American Health Organization and World Health Organization (WHO) (2015), Cuban Experience with Local Production of Medicines, Technology Transfer and Improving Access to Health, Geneva: WHO.

European Federation of Pharmaceutical Industries and Association (EFPIA) (2017), The Pharmaceutical Industry in Figures, Key Data 2017, available at: https://www.efpia.eu/media/219735/efpia-pharmafigures2017_statisticbroch_v04-final.pdf.

EvaluatePharma [annual], World Preview, London: Evaluate.

EvaluatePharma, World Preview 2013, Outlook to 2018: Returning to Growth, available at: https://info.evaluategroup.com/worldpreview2018_fp_lp.html.

EvaluatePharma (2018a), Orphan Drug Report 2018, 5th Edition, London: Evaluate.

EvaluatePharma (2018b), World Preview 2018, Outlook to 2024, available at: <https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2018-outlook-2024#download>.

Ewen, M., Joosse, H-J, Beran, D. and Laing, R. (2019), "Insulin prices, availability and affordability in 13 low-income and middle-income countries", *BMJ Global Health* 4(3): e001410.

Eyquem, J., Mansilla-Soto J., Giavridis, T., van der Stegen, S. J., Hamieh, M., Cunanan, K. M. et al. (2017), "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection", *Nature* 543(7643): 113–117.

Ferreira, R., David, F. and Nielsen, J. (2018), "Advancing biotechnology with CRISPR/Cas9: Recent applications and patent landscape", *Journal of Industrial Microbiology & Biotechnology* 45(7): 467–480.

Fink, C. (2011), "Intellectual Property Rights", in Chauffour, J.-P. and Maur, J.-C. (eds.), *Preferential Trade Agreement Policies for Development: A Handbook*, Washington, DC: World Bank.

Flynn, S. M., Hollis, A. and Palmedo, M. (2009), "An economic justification for open access to essential medicine patents in developing countries", *Journal of Law, Medicine and Ethics* 37(2): 184–208.

Fojo, T., Mailankody, S. and Lo, A. (2014), "Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture", *JAMA Otolaryngology – Head & Neck Surgery* 140(12):1225–1236.

da Fonseca, E. M., Shadlen, K. and Bastos, F. I. (2019), "Brazil's fight against hepatitis C: Universalism, local production, and patents", *New England Journal of Medicine* 380: 605–607.

Fontein, C., Akker, I. and Sauter, W. (2018), "Reconciling competition and IP law: the case of patented pharmaceuticals and dominance abuse", ACM Working Paper, available at: <http://eplaw.org/wp-content/uploads/2018/03/ACM-working-paper->

Gainey, L. (2018), "How the EPO treats personalised healthcare patents", *Life Sciences Intellectual Property Review*, online version, 12 October 2018.

Gammie, T., Lu, C. Y., and Babar Z. U. (2015), "Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries", *PLoS ONE*, 9 October 2015; 10: e0140002.

Gapper, J. (2019), "Keytruda shows the high price of curing cancer," *Financial Times*, online version, 13 February 2019, <https://www.ft.com/content/c1dacca6-2ec2-11e9-ba00-0251022932c8>.

Garner, S., Rintoul, A. and Hill, S. R. (2018), "Value-based pricing: L'enfant terrible?", *Pharmacoeconomics* 36(1): 5–6.

Garrido, M. V., Kristensen, F. B., Nielsen, C. P. and Busse, R. (2008), *Health Technology Assessment and Health Policy-Making in Europe: Current Status, Challenges and Potential*, Observatory Studies Series No. 14, Geneva: WHO for the European Observatory on Health Systems and Policies.

Gaudillière, J. (2008), "How pharmaceuticals became patentable: the production and appropriation of drugs in the twentieth century", *History and Technology*, 24: 99–106.

Gavi (2018), *Advance Market Commitment for Pneumococcal Vaccines, Annual Report 1 January – 31 December 2018*, available at: <https://www.gavi.org/investing/innovative-financing/pneumococcal-amc/>.

Gavi (2019), *How We Work Together: Quick start guide for new members of the Vaccine Alliance*, available at: <https://www.gavi.org/library/publications/gavi/how-we-work-together/>.

GE Healthcare (2011), "Market-relevant design: Making ECGs available across India", *The Pulse on Health, Science & Tech*, 30 SeptahR1–6.iORSr avrPrnnv rary/54, T raSpecanceT(iv.,ohlido, ns.)15 ()TJ0 -1.467 TDanschaope, E. etch c Ldf0 Tw 0 8 0 0 8 459.ii015 pfcdmif0 Tc (,)Tj0.015 T.0 -1.467 TD(ava266.)Tj0 -2.(o:he bw2Biosims Ir)Tjitiing/

- Ivanovska, V., Rademaker, C. M. A., van Dijk, L., Mantel-Teeuwisse, A. K. (2014), "Pediatric drug formulations: A review of challenges and progress", *Pediatrics* 134(2): 361–372.
- Iyengar, S., Tay-Teo, K., Vogler, S., Beyer, P., Wiktor, S., de Joncheere, K. et al. (2016), "Prices, costs, and affordability of new medicines for Hepatitis C in 30 countries: An economic analysis", *PLOS Medicine* 13(5): e1002032.
- Jamison, D. T., Summers, L. H., Alleyne, G., Arrow, K. J., Berkley, S., Binagwaho, A. et al. (2013), "Global health 2035: A world converging within a generation", *The Lancet* 382: 1898–1955.
- Jaspers, L., Colpani, V., Chaker, L., van der Lee, S. J., Muka, T., Imo, D. et al. (2015), "The global impact of non-communicable diseases on households and impoverishment: A systematic review", *European Journal of Epidemiology* 30(3): 163–188.
- Jayasundara, K., Hollis, A., Krahn, M., Mamdani, M., Hoch, J. S. and Grootendorst, P. (2019), "Estimating the clinical cost of drug development for orphan versus non-orphan drugs", *Orphanet Journal of Rare Diseases* 14: 12.
- Jena, A. B., Ho, O., Goldman, D. P. and Karaca-Mandic, P. (2015), "The impact of the US Food and Drug Administration chlorofluorocarbon ban on out-of-pocket costs and use of Albuterol inhalers among individuals with asthma", *JAMA Internal Medicine* 175(7): 1171–1179.
- Jenner, A., Bhagwandin, N. and Kowalski, S. (2017), *Antimicrobial Resistance (AMR) and Multidrug Resistance (MDR): Overview of Current Approaches, Consortia and Intellectual Property Issues*, Geneva: WIPO.
- Jewell, C. and Balakrishnan, V. S. (2017), "The battle to own the CRISPR–Cas9 gene-editing tool", *WIPO Magazine* 2, online version, April 2017.
- de Jongh, T., Radauer, A., Bostyn, S. and Poort, J. (2018), *Effects of Supplementary Protection Mechanisms for Pharmaceutical Products: Final Report*, May 2018, Amsterdam: Technopolis Group.
- Jürgens, B. and Clarke, N. S. (2019), "Evolution of CAR T-cell immunotherapy in terms of patenting activity", *Nature Biotechnology* 37: 370–375.
- Kahn, J. and Lauerman, J. (2018), "Google taking over health records raises patient privacy fears", *Bloomberg*, online version, 21 November 2018.
- Kaltenboeck, A. and Bach, P. B. (2018), "Value-based pricing for drugs: Theme and variations", *JAMA* 319(21): 2165–2166.
- Kampf, R. (2015), "Special Compulsory Licences for Export of Medicines: Key Features of WTO Members' Implementing Legislation", *Staff Working Paper ERSD-2015-07*, Geneva: WTO.
- Kaplan, W. A. and Beall, R. F. (2016), "The global intellectual property ecosystem for insulin and its public health implications: An observational study", *Journal of Pharmaceutical Policy and Practice* 10: 3.
- Kartikeyan, S., Bharmal, R. N., Tiwari, R. P. and Bisen, P. S. (2007), *HIV and AIDS: Basic elements and priorities*, Dordrecht: Springer, 2007.
- Kesselheim, A. S. (2010) "Using market-exclusivity incentives to promote pharmaceutical innovation", *New England Journal of Medicine* 363: 1855–1862.
- Kesselheim, A. S., Misono, A. S., Shrank, W. H., Greene, J. A., Doherty, M., Avorn, J. et al. (2013), "Variations in pill appearance of antiepileptic drugs and the risk of nonadherence", *JAMA Internal Medicine* 173(3): 202–208.
- Kesselheim, A. S. and Solomon, D. H. (2010), "Incentives for drug development—the curious case of colchicine", *New England Journal of Medicine* 362: 2045–2047.
- Khor, M. (2007), "Patents, Compulsory Licences and Access to Medicines: Some Recent Experiences", *TWN Intellectual Property Series 10*, Penang, Malaysia: Third World Network (TWN).
- Kim, C. and Prasad, V. (2015), "Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals", *JAMA Internal Medicine* 359: 1992–1994.
- King, D. R. and Kanavos, P. (2002), "Encouraging the use of generic medicines: Implications for transition economies", *Croatian Medical Journal* 43(4): 462–69.
- Kittittrakul, C. (2018a), presentation at the Academic Forum on Lessons Learned of Drug Patents' Opposition and Withdrawal in Thailand, held at the Faculty of Pharmaceutical Science, Chulalongkorn University, 18 May 2018.
- Kittittrakul, C. (2018b), presentation at the Civil Society Organizations' Meeting on Hepatitis C: Emerging Evidences and Scaling-up Response, Bangkok, 6–7 June 2018.
- Kmietowicz, Z. (2015a), "Campaigners demand right to generic version of breast cancer drug", *BMJ* 351: h5279.
- Kmietowicz, Z. (2015b), "China rejects patent on hepatitis C drug sofosbuvir", *BMJ* 350: h3429.
- Kneller, R. (2010), "The importance of new companies for drug discovery: Origins of a decade of new drugs", *Nature Reviews Drug Discovery* 9: 1–10.

the Management of Intellectual Property in Health Research and Development (MIHR) and Public Intellectual Property Resource for Agriculture (PIPRA): 739–745.

Krattiger, A., Bombelles, T., Bartels, H. G., Mirza, Z., Beyer, P., Taubman, A. et al. (2015), "Promoting Medical Innovation and Access Together: Trilateral Cooperation between WHO, WIPO and WTO", *Global Challenges Brief on Trilateral Cooperation*, Geneva: WIPO.

Kulkarni, P.S., Socquet, M., Jadhav, S.S., Kapre, S.V., LaForce, F.M. and Poonawalla, C.S. (2015), "Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective from the Serum Institute of India", *Clinical Infectious Diseases* 61: S483–S488.

Kwon, D. (2019), "A brief guide to the current CRISPR landscape", *The Scientist*, online version, 15 July 2019.

Kyle, M. and Qian, Y. (2014), "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS", Working Paper No. 20799, Cambridge (MA): National Bureau of Economic Research (NBER).

LaMattina, J. L. (2011), "The impact of mergers on pharmaceutical R&D",

direct-acting antiviral drugs for HCV infection in Europe”, *The Lancet Gastroenterology & Hepatology* 3(2): 125–133.

Martin-Laffon, J., Kuntz, M. and Ricroch, A. E. (2019), “Worldwide CRISPR patent landscape shows strong geographical biases”, *Nature Biotechnology* 37: 613–620.

Martinez, C. (2010), “Insight into Different Types of Patent Families”, *OECD Science, Technology and Industry Working Papers No. 2010/02*, Paris: OECD Publishing.

Masini, T., Hauser, J., Kuwana, R., Nhat Linh, N. and Jaramillo, E. (2018), “Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?” *European Respiratory Journal* 51(3): 1702480.

Masum, H. and Harris, R. (2011), *Open Source for Neglected Disease: Magic Bullet or Mirage?*, Washington, DC: Results for Development Institute.

Matthijs, G. and van Ommen, G.-J. B. (2009), “Gene Patents: From Discovery to Invention. A Geneticist’s View”, in Van Overwalle, G. (ed.), *Gene Patents and Collaborative Licensing Models: Patent Pools, Clearinghouses, Open Source Models and Liability Regimes*, Cambridge (UK): Cambridge University

Murray, C. J. L. and Lopez, A. D. (eds.) (1996), *The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020*, Boston (MA): Harvard School of Public Health.

National Institutes of Health (NIH) (2001), *Glossary of Terms for Human Subjects Protection and Inclusion Issues*, Washington, DC: NIH.

National Research Council (2003), *Patents in the Knowledge-Based Economy*. Washington, DC: The National Academies Press, available at: <https://doi.org/10.17226/10770>.

National Research Council (2011), *Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease*. Washington, DC: The National Academies Press, available at: <https://doi.org/10.17226/13284>.

NCD Alliance (2011), "Access to Essential Medicines and Technologies for NCDs", Briefing Paper, Geneva: NCD Alliance.

Newsome, C. (2017), "Basaglar", *Clinical Diabetes* 35(3): 181.

Nguyen, T-Y, Veras, J and Shahzad, M. (2018), "Recent Experiences in Policy Implementation of Socially Responsible Licensing in Select Universities Across Europe and North America: Identifying Key Provisions to Promote Global Access to Health Technologies", *Les Nouvelles: The Journal of the Licensing Executives Society International* LIII(3).

Niëns, L., Cameron, A., Van de Poel, E., Ewen, M., Brouwer, W. B. and Laing, R. (2010), "Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world", *PLoS Medicine* 7(8): e1000333.

Niraula, S., Seruga, B., Ocana, A., Shao, T., Goldstein, R., Tannock, I. F. et al. (2012), "The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs", *Journal of Clinical Oncology* 30(24): 3012–3019.

Nunn, A. S., Fonseca, E. M., Bastos, F. I., Gruskin, S. and Salomon, J. A. (2007), "Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment", *PLoS Medicine* 4(11): e305.

Obrist, B., Iteba, N., Lengeler, C., Makemba, A., Mshana, C., Nathan, R. et al. (2007), "Access to health care in contexts of livelihood insecurity: A framework for analysis and action", *PLoS Medicine* 4(10): e308.

Office of the United Nations High Commissioner for Human Rights (OHCHR) and World Health Organization (WHO) (2008), "The Right to Health", Fact Sheet No. 31, Geneva: OHCHR and WHO.

Olcay, M. and Laing, R. (2005), "Pharmaceutical Tariffs: What is Their Effect on Prices, Protection of Local Industry and Revenue Generation?: Prepared for: The Commission on Intellectual Property Rights, Innovation and Public Health", Geneva: WHO.

Olliaro, P. L., Kuesel, A. C., Halleux, C. M., Sullivan, M. and Reeder, J. C. (2018), "Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years", *PLoS Neglected Tropical Diseases* 12(11): e0006837.

Olson, L. M. and Wendling, B. W. (2013), "The Effect of Generic Drug Competition on Generic Drug Prices during the Hatch-Waxman 180-day Exclusivity Period", Working Paper No. 317, FTC Bureau of Economics, Washington, DC.

Olson, S. and Berger, A. (2011), *Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Drug Development: Workshop Summary*, Washington, DC: National Academies Press.

O'Neill, J. (2016), *The Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations*, available at: [https://amr-review.org/sites/default/files/160525_Final paper_with cover.pdf](https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf).

Organisation for Economic Co-operation and Development (OECD) (2008), *Pharmaceutical Pricing Policies in a Global Market*, Paris: OECD.

Organisation for Economic Co-operation and Development (OECD) (2017a), *Health at a Glance 2017: OECD Indicators*, Paris: OECD.

Organisation for Economic Co-operation and Development (OECD) (2017b), *Tackling Wasteful Spending on Health*, available at: <https://www.oecd.org/els/health-systems/Tackling-Wasteful-Spending-on-Health-Highlights-revised.pdf>.

Organisation for Economic Co-operation and Development (OECD) (2018), "Pharmaceutical Innovation and Access to Medicines", *OECD Health Policy Studies*, p. 143, available at: <http://www.oecd.org/health/pharmaceutical-innovation-and-access-to-medicines-9789264307391-en.htm>.

Organisation for Economic Co-operation and Development (OECD) and European Union Intellectual Property Office (EUIPO) (2019), *Trends in Trade in Counterfeit and Pirated Goods*, Paris: OECD Publishing.

Organisation of Eastern Caribbean States (OECS) (2001), *PMLTJs Press*.

(framework baevehealtug-HIV exTjiePari -1low-T)Tmiddle4 TDD((in(deeelo67 ie 1 T

von Philipsborn, P., Steinbeis, F., Bender, M. E., Regmi, S. and Tinnemann, P. (2015), "Poverty-related and neglected diseases: An economic and epidemiological analysis of poverty relatedness and neglect in research and development", *Global Health Action* 8(1), online version, 22 January 2015.

PhRMA, PhRMA Annual Membership Survey 2018, available at: <https://heatinformatics.com/posts/2018-phrma-annual-membership-survey>.

Prasad, V. and Mailankody, S. (2017), "Research and development spending to bring a single cancer drug to market and revenues after approval", *JAMA Internal Medicine* 177(11): 1569–1575.

Pray, L. (2008), "Personalized medicine: Hope or hype?," *Nature Education* 1(1):72.

Price, W. N. and Rai, A. K. (2015), "Are trade secrets delaying biosimilars?," *Science* 348(6231): 188–189.

Price, W. N. and Rai, A. K. (2016), "Manufacturing barriers to biologics competition and innovation", *Iowa Law Review* 101(3): 1023–1063.

Pricewaterhousecoopers International Ltd (PwC) (2008), *Pharma 2020: Virtual R&D – Which Path Will You Take?*, PwC.

Pulcini, C., Mohrs, S., Beovic, B., Gyssens, I., Theuretzbacher, U. and Cars, O. (2016), "Forgotten antibiotics: A follow-up inventory study in Europe, the USA, Canada and Australia", *International Journal of Antimicrobial Agents* 49(1): 98–101.

Quinn, R. (2013), "Rethinking antibiotic research and development: World War II and the penicillin collaborative", *American Journal of Public Health* 103(3): 426–434.

Quintilio, W., Kubrusly, F.S., Iourtov, D., Miyaki, C., Sakauchi, M.A., et al. (2009), "Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice", *Vaccine* 27(31): 4219–4224.

Rägo, L. and Santoso, B. (2008), "Drug Regulation: History, Present and Future", in van Boxtel, C. J., Santoso, B. and Edwards, I. R. (eds.), *Drug Benefits and Risks: International Textbook of Clinical Pharmacology*, 2nd Edition, Amsterdam: IOS Press.

Rao, A. (2011), "New technologies for neglected diseases: Can tax credits help biotechnology companies advance global health?" *Journal of Commercial Biotechnology* 17: 290–292, available at: <https://paperity.org/p/76961659/new-technologies-for-neglected-diseases-can-tax-credits-help-biotechnology-companies>.

Reardon, S. (2014), "Ebola treatments caught in limbo", *Nature* 511(7511): 520.

Reátegui Valdiviezo, M. (2016), "Datos de Prueba de Productos Farmacéuticos. Análisis de la Legislación Peruana y Tratados Aplicables",

- Sagonowsky, E. (2018), "Merck Starts Rolling FDA Submission for Its Ebola Vaccine, Aiming to Finish Next Year", Fiercepharma, online version, 15 November 2018, available at: <https://www.fiercepharma.com/vaccines/merck-starts-fda-submission-for-ebola-vaccine-aiming-to-finish-next-year>.
- El Said, M. K. (2010), *Public Health Related Trips-Plus Provisions in Bilateral Trade Agreements: A Policy Guide for Negotiators and Implementers in the WHO Eastern Mediterranean Region*, Geneva: WHO and ICTSD.
- Sampat, B. N. (2015), "Intellectual Property Rights and Pharmaceuticals: The Case of Antibiotics", *Economic Research Working Paper No. 26*, Geneva: WIPO.
- Sampat, B. N. and Shadlen, K. (2016), *The Effects of Restrictions on Secondary Pharmaceutical Patents: Brazil and India in Comparative Perspective*, available at: <http://www.hbs.edu/faculty/Lists/Events/Attachments/1124/Secondary%20Pharma.pdf>.
- Sanchez-Luna, M., Burgos-Pol, R., Oyagüez, I., Figueras-Aloy, J., Sánchez-Solis, M., Martín-Torres, F. et al. (2017), "Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: Update based on the clinical evidence in Spain", *BMC Infectious Diseases* 17(1): 687.
- Sarbacker, G. B. and Urteaga, E. M. (2016), "Adherence to Insulin Therapy", *Diabetes Spectrum* 29(3): 166–170.
- Savedoff, W. D. (2011), "Governance in the Health Sector: A Strategy for Measuring Determinants and Performance", *Policy Research Working Paper No. 5655*, Washington, DC: World Bank.
- Scaria, A. G. and Mammen, K. S. (2018), "Non-Traditional Marks in the Pharmaceutical Sector: Non-Traditional Barriers to Access to Medicine?" in Calboli, I. and Senftleben, M. (eds.), *The Protection of Non-Traditional Trademarks: Critical Perspectives*, Oxford: Oxford University Press.
- Schafer, J., Tapella, M., Kantarelis, T. (2016), "Biosimilars: Why deep discounts may become the dominant paradigm", *Pharmaceutical Commerce*, online version, 22 February 2016.
- Schell, J. (2013), "Neurim: a new definition of 'product' in supplementary protection certificates?", *Journal of Intellectual Property Law & Practice* 8(9): 723–728, available at: <https://doi.org/10.1093/jiplp/jpt130>.
- Scherer, F. M. and Watal, J. (2002), "Post-TRIPS options for access to patented medicines in developing nations", *Journal of International Economic Law* 5(4): 913–939.
- Schmucker, C., Schell, L. K., Portalupi, S., Oeller, P., Cabrera, L., Bassler, D. et al. (2014), "Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries", *PLoS ONE* 9: e114023.
- Schuhmacher, A., Gassman, O. and Hinder, M. (2016), "Changing R&D models in research-based pharmaceutical companies", *Journal of Translational Medicine*, 14(1): 105.
- Schuhmacher, A., Gassman, O., McCracken, N. and Hinder, M. (2018), "Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?", *Journal of Translational Medicine* 16:119.
- Schwieterman, W. D. (2006), "Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective", *Drug Discovery Today* 11(19–20): 945–951.
- Scutti, S. (2018), "Gene therapy for rare retinal disorder to cost \$425,000 per eye", CNN, online version, 3 January 2018, available at: <https://www.cnn.com/2018/01/03/health/luxturna-price-blindness-drug-bn/index.html>.
- Shapiro, C. (2001), "Navigating the Patent Thicket: Cross Licences, Patent Pools and Standard Setting", in Jaffe, A. B., Lerner, J. and Stern, S. (eds.), *Innovation Policy and the Economy*, vol. 1, Cambridge (MA): MIT Press.
- Shcherbakova, N., Shepherd, M., Lawson, K. and Richards, K. (2011), "The role of authorized generics in the prescription drug marketplace", *Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector* 8: 28–40.
- Shedden, K. (2018), presentation at Sustainable Development Goals: Innovative Technologies to Promote Healthy Lives and Well-being, A Joint Technical Symposium by the WHO, WIPO and WTO, Geneva, 26 February 2018.
- Shum, T., Kruse, R. L. and Rooney, C. M. (2018), "Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities", *Expert Opinion on Biological Therapy* 18(6): 653–664.
- Silverman, E. (2017a), "Netherlands health minister threatens compulsory licenses over 'absurd prices'", *STAT News*, available at: <https://www.statnews.com/pharmalot/2017/11/27/netherlands-patents-compulsory-licenses-vertex/>.
- Silverman, E. (2017b), "Under pressure, Gilead expands Sovaldi licensing deal to four middle-income countries", *STAT News*, available at: <https://www.statnews.com/pharmalot/2017/08/24/gilead-sovaldi-malaysia-ukraine/>.
- Simon-Kucher & Partners (2016), *Payers' Price & Market Access Policies Supporting a Sustainable Biosimilar Medicines Market: Final Report*, Bonn: Simon-Kucher & Partners.
- Son, K., Lopert, R., Gleeson, D. and Lee, T. (2018), "Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States", *Globalization and Health* 14(101), available at: <https://doi.org/10.1186/s12992-018-0423-0>.
- Srivastava, R. K. and More, A. T. (2010), "Some aesthetic considerations for over the-counter (OTC) pharmaceutical products", *International Journal of Biotechnology* 11(3-4): 267–283.
- Stanaway, J. D., Afshin, A., Gakidou, E., Lim, S. S., Abate, D., Abate, K. H., et al. (2018), "Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017", *The Lancet* 392(10159): 1923–1994.
- Stenberg, K., Hanssen, O., Edejer, T. T., Bertram, M., Brindley, C., Meshreky, A. et al. (2017), "Financing transformative health systems towards achievement of the health Sustainable Development Goals: A model for projected resource needs in 67 low-income and middle-income countries", *The Lancet Global Health* 5(9): e875–e887.
- Stevens, A. J. and Effort, A. E. (2008), "Using academic license agreements to promote global social responsibility", *Les Nouvelles* 43: 85.
- Stevens, A. J., Jensen, J. J., Wyller, K., Kilgore, P. C., Chattergee, S. and Rohrbaugh, M. L. (2011), "The role of public-sector

research in the discovery of drugs and vaccines", *New England Journal of Medicine* 364(6): 535–541.

Sussex, J., Feng, Y., Mestre-Ferrandiz, J., et al. (2016), "Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom", *BMC Medicine* 14(32), online version, 25 February 2016.

Tängdén, T., Pulcini, C., Aagaard, H., Balasegaram, M., et al. (2018), "Unavailability of old antibiotics threatens effective treatment for common bacterial infections", *The Lancet Infectious Diseases* 18(3): 242–244.

Tay-Teo, K., Ilbawi, A. and Hill, S. R. (2019), "Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies", *JAMA Network Open* 2(1): e186875.

Taylor, C. T. and Silberston, Z. A. (1973), *The Economic Impact of the Patent System: A Study of the British Experience*, Cambridge: Cambridge University Press.

Temin, P. (1979), "Technology, regulation, and market structure in the modern pharmaceutical industry", *The Bell Journal of Economics* 10(2): 429–446.

Tenn, S. & Wendling, B. W. (2014), "Entry threats and pricing in the generic drug industry", *Review of Economics and Statistics* 96: 214–228.

Thomas, J. R. (2014), *The Role of Patents and Regulatory Exclusivities in Pharmaceutical Innovation*, Washington, DC: Congressional Research Service.

Thomas, J. R. (2015), *Pharmaceutical Patent Law*, 3rd Edition, Arlington (VA): Bloomberg BNA.

Todd, Matthew (2010), "A Summary of What Is Needed Right Now", *The Synaptic Leap's Synthetic Praziquantel Project*, available at: <http://www.thesynapticleap.org/node/286>.

Toebes, B., Ferguson, R., Markovic, M. M. and Nnamuchi, O. (eds.) (2014), *The Right to Health, A Multi-Country Study of Law, Policy and Practice*, Den Haag: Asser Press.

Toland, A. E., Forman, A., Couch, F. J., Culver, J. O., et al. on behalf of the BIC Steering Committee (2018), "Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices", *npj Genomic Medicine* 3(7), available at: [10.1038/s41525-018-0046-7](https://doi.org/10.1038/s41525-018-0046-7).

Tomas Gomez-Arostegui, H. (2010), "Prospective Compensation in Lieu of a Final Injunction in Patent and Copyright Cases", *Fordham Law Review* 78(4), available at: <http://ir.lawnet.fordham.edu/flr/vol78/iss4/2>.

Topol, E. J. (2019), "High-performance medicine: The convergence of human and artificial intelligence", *Nature Medicine* 25: 44–56.

pe:n (VA): Bloomberg BNA.UnitowN]TJ0srDevelopm-1.vailgramm5 (UNDPRight to7 Patent Law)Tj/T1_edicine o3High-(Unitow. J. roi,3.168tegudTsnN]TJ0sr

Watal, J. (2001), "Workshop on Differential Pricing and Financing of Essential Drugs: Background Note Prepared by Jayashree Watal, Consultant to the WTO Secretariat", Geneva: WTO.

Watal, J. and Dai, R. (2019), "Product Patents and Access to Innovative Medicines in a Post-TRIPS-Era", Staff Working Paper ERSD-2019-05, Geneva: WTO.

Weires, R. (2019), "Recent advances in biologics manufacturing diminish the importance of trade secrets: a response to Price and Rai", Written Description, 4 March 2019.

Welch, A. R. (2016a), "The Norwegian biosimilar phenomenon: From biosimilar to 'biogeneric'", Biosimilar Development, online version, 26 July 2016.

Welch, A. R. (2016b), "What to know about emerging market biosimilar pathways", Biosimilar Development, online version, 24 June 2016.

Wendland, W. and Jiao, F. (2018), "Intellectual Property Rights and Traditional Medical Knowledge in Africa: Issues and Development", in Wambebe, C. (ed.), *African Indigenous Medical Knowledge and Human Health: Research, Development, and Delivery*, Boca Raton (FL): CRC Press.

West, D. M., Villasenor, J. and Schneider, J. (2017), *Private Sector Investment in Global Health R&D: Spending Levels, Barriers and Opportunities*, Washington, DC: The Brookings Institution.

Wieseler, B., McGauran, N. and Kaiser, T. (2019), "New drugs: where did we go wrong and what can we do better?", *BMJ* 366: l4340.

Williams, H. L. (2017), "How do patents affect research investments?", *Annual Review of Economics* 9: 441–469.

Wingrove, J. (2019), "SPC waiver may drive innovator investment in secondary patents and litigation", *Patent Strategy*, online version, 9 May 2019, available at: <https://patentstrategy.managingip.com/Articles/38>.

Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., et al. (2017), "Essential medicines for universal health coverage", *The Lancet* 389(10067): 403–476.

Workman, P., Draetta, G. F., Schellens, J. H. M. and Bernards, R. (2017), "How much longer will we put up with \$100,000 cancer drugs?", *Cell* 168(4): 579–583.

World Bank (2005), *A Guide to Competitive Vouchers in Health*, Washington, DC: World Bank.

World Bank (2009), "Europe and Central Asia: Health Insurance and Competition", Report No. 44316-ECA, Washington, DC: World Bank.

World Health Organization (WHO) (2000), *The World Health Report 2000: Health Systems: Improving Performance*, Geneva: WHO.

World Health Organization (WHO) (2001a), *Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health*, Geneva: WHO.

The Lancet

quality, safety and efficacy such as substandard/spurious/falsely-labelled/falsified/counterfeit medical products" (A/SSFFC/WG/3 Rev.1), 17 February 2011.

World Health Organization (WHO) (2012), Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination: Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination, Geneva: WHO.

World Health Organization (WHO) (2013a), Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020, Geneva: WHO, available at: https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236_eng.pdf?sequence=1.

World Health Organization (WHO) (2013b), Weekly Epidemiological Record 1(88): 1–16, available at: <https://www.who.int/wer/2013/wer8801.pdf?ua=1> www.who.int/immunization_delivery/new_vaccines/technologies_aerosol/en/.

World Health Organization (WHO) (2014a), Access to Antiretroviral Drugs in Low- and Middle-Income Countries, Technical Report, Geneva: WHO.

World Health Organization (WHO) (2014b), Guidelines for the Screening, Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection, Geneva: WHO.

World Health Organization (WHO) (2014c), Hepatitis E Vaccine: Composition, Safety, Immunogenicity and Efficacy, A document prepared for Strategic Advisory Group of Experts on Antiretroviral Therapy for HIV, Geneva: WHO, available at: http://apps.who.int/iris/bitstream/handle/10665/112622/1/9789241506236_eng.pdf?sequence=1.

- World Health Organization (WHO) (2018b), *Assessing National Capacity for the Prevention and Control of Noncommunicable Diseases: Report of the 2017 Global Survey*, Geneva: WHO.
- World Health Organization (WHO) (2018c), *Facilitating Access and Benefit-Sharing (ABS) for Pathogens to Support Public Health: Workshop Report: 11–12 June 2018 Workshop*, September 2018, Geneva: WHO.
- World Health Organization (WHO) (2018d), *Global Vaccine Action Plan: Monitoring, Evaluation & Accountability: Secretariat Annual Report 2018*, Geneva: WHO.
- World Health Organization (WHO) (2018e), *Progress Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers in Low- and Middle-income Countries*, Geneva: WHO.
- World Health Organization (WHO) (2018f), *Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis (MDR/RR-TB)*, Geneva: WHO.
- World Health Organization (WHO) (2018g), *Technical Report: Pricing of Cancer Medicines and Its Impacts: A Comprehensive Technical Report for the World Health Assembly Resolution 70.12: Operative Paragraph 2.9 on Pricing Approaches and Their Impacts on Availability and Affordability of Medicines for the Prevention and Treatment of Cancer*. Geneva: WHO, available at: <https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115-eng.pdf?ua=1>.
- World Health Organization (WHO) (2018h), *Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV: Interim Guidelines: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection*, Geneva: WHO.
- World Health Organization (WHO) (2018i), *WHO EML cancer medicines working group (CMWG): report of the meeting 22-23 March 2018*, Geneva, Switzerland. Geneva: WHO, available at: <https://apps.who.int/iris/bitstream/handle/10665/272962/WHO-EMP-IAU-2018.03-eng.pdf?sequence=1&isAllowed=y>.
- World Health Organization (WHO) (2019a), *Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline*, Geneva: WHO.
- World Health Organization (WHO) (2019b), *Executive Summary: The Selection and Use of Essential Medicines 2019: Report of the 22nd WHO Expert Committee on the Selection and Use of Essential Medicines, 1–5 April 2019*, Geneva: WHO.
- World Health Organization (WHO) (2019c), *Global Tuberculosis Report 2019*, Geneva: WHO.
- World Health Organization (WHO) (2019d), *Pandemic Influenza Preparedness Framework: Annual Progress Report 1 January–31 December 2018*, Geneva: WHO.
- World Health Organization (WHO) (2019e), *“Universal health coverage (UHC)”, 24 January 2019*.
- World Health Organization (WHO) (2019f), *WHO Global Report on Traditional and Complementary Medicine*, Geneva: WHO.
- World Health Organization (WHO) and Health Action International (HAI) (2008), *Measuring Medicine Prices, Availability, Affordability and Price Components*, Geneva and Amsterdam: WHO and HAI.
- World Health Organization (WHO) and International Bank for Reconstruction and Development / The World Bank (2020), *Global Monitoring Report on Financial Protection in Health 2019*, Geneva: WHO.
- World Health Organization (WHO) and UNAIDS (2000), *Patent situation of HIV/AIDS-related drugs in 80 countries*, available at: <https://www.who.int/3by5/en/patentshivdrugs.pdf>.
- World Health Organization (WHO) and World Trade Organization (WTO) (2002), *WTO Agreements & Public Health: A Joint Study by the WHO and the WTO Secretariat*, Geneva: WHO and WTO.
- World Health Organization (WHO), *Market Information for Access to Vaccines (MI4A) and WHO Vaccine Product, Price and Procurement (V3P) (2018)*, *Global Vaccine Market Report*, available at: https://www.who.int/immunization/programmes_systems/procurement/v3p/platform/module2/MI4A_Global_Vaccine_Market_Report.pdf?ua=1.
- World Health Organization (WHO) Regional Office for Europe (2019), *Can people afford to pay for health care? New evidence on financial protection in Europe*, Copenhagen: WHO Regional Office for Europe.
- World Intellectual Property Organization (WIPO) (2001), *Intellectual Property Needs and Expectations of Traditional Knowledge Holders: WIPO Report on Fact-Finding Missions on Intellectual Property and Traditional Knowledge (1998–1999)*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2007), *The 45 Adopted Recommendations under the WIPO Development Agenda*, available at www.wipo.int/ip-development/en/agenda/recommendations.html.
- World Intellectual Property Organization (WIPO) (2009), *The Economics of Intellectual Property: Suggestions for Further Research in Developing Countries and Countries with Economies in Transition*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2011a), *“WIPO Patent Search Report on Pandemic Influenza Preparedness (PIP)-Related Patents and Patent Applications”*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2011b), *World Intellectual Property Report: The Changing Face of Innovation*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2014a), *Alternatives in Patent Search and Examination: Policy Guide*, Geneva: WIPO.
- World Intellectual Property Organization (WIPO) (2014b), *“Patent*

